SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2023
Commission File Number: 001-40277
OLINK HOLDING AB (PUBL)
(Exact Name of Registrant as Specified in its Charter)
Uppsala Science Park
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
On August 29, 2023, Olink Holding AB (publ) issued a news release announcing its participation in multiple September investor events, a copy of which is furnished as Exhibit 99.1.
Exhibit No. Description
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
OLINK HOLDING AB (PUBL)
By: /s/ Jon Heimer
Title: Chief Executive Officer
Date: August 29, 2023
Olink to participate in September investor events
UPPSALA, Sweden, August 29, 2023 -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events:
•Goldman Sachs 20th Annual European Medtech and Healthcare Services Conference
Thursday, September 7th at 7:15 am ET
•Morgan Stanley 21st Annual Global Healthcare Conference
Tuesday, September 12th at 1:35 pm ET
A live and archived webcast of the Morgan Stanley fireside chat will be available on the “Events” section of the Company’s website at https://investors.olink.com/news-events/events.
Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
Michael B. Gonzales VP Global Marketing
Mobile: +1 415 308 6467